{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:28:13Z","timestamp":1787585293327,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Research Funds of Science & Technology Department of Sichuan Province","award":["2021YJ0134"],"award-info":[{"award-number":["2021YJ0134"]}]},{"name":"the Research Funds of Science & Technology Department of Sichuan Province","award":["2019YFS0514"],"award-info":[{"award-number":["2019YFS0514"]}]},{"name":"the Research Project of Chengdu Science and Technology Bureau","award":["2022-YF05-01611-SN"],"award-info":[{"award-number":["2022-YF05-01611-SN"]}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["ZYGX2019J106"],"award-info":[{"award-number":["ZYGX2019J106"]}]},{"name":"the Open Project of Radiation Oncology Key Laboratory of Sichuan Province","award":["2020FSZLX04"],"award-info":[{"award-number":["2020FSZLX04"]}]},{"name":"the National Key Research and Development Program of China","award":["2020YFC2005500"],"award-info":[{"award-number":["2020YFC2005500"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00280-023-04521-y","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T18:02:51Z","timestamp":1679335371000},"page":"303-315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways"],"prefix":"10.1007","volume":"91","author":[{"given":"Xuerun","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyou","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1901-9698","authenticated-orcid":false,"given":"Lei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"key":"4521_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4521_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ et al (2022) Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:167\u2013192. https:\/\/doi.org\/10.6004\/jnccn.2022.0008","journal-title":"J Natl Compr Canc Netw"},{"key":"4521_CR3","doi-asserted-by":"publisher","first-page":"5672","DOI":"10.3748\/wjg.v20.i19.5672","volume":"20","author":"E Bollschweiler","year":"2014","unstructured":"Bollschweiler E, Berlth F, Baltin C et al (2014) Treatment of early gastric cancer in the Western World. World J Gastroenterol 20:5672\u20135678. https:\/\/doi.org\/10.3748\/wjg.v20.i19.5672","journal-title":"World J Gastroenterol"},{"key":"4521_CR4","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s10555-020-09925-3","volume":"39","author":"RE Sexton","year":"2020","unstructured":"Sexton RE, Al Hallak MN, Diab M, Azmi AS (2020) Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev 39:1179\u20131203. https:\/\/doi.org\/10.1007\/s10555-020-09925-3","journal-title":"Cancer Metastasis Rev"},{"key":"4521_CR5","doi-asserted-by":"publisher","first-page":"e10786","DOI":"10.1097\/MD.0000000000010786","volume":"97","author":"H-M Dong","year":"2018","unstructured":"Dong H-M, Wang Q, Wang W-L et al (2018) A clinical analysis of systemic chemotherapy combined with radiotherapy for advanced gastric cancer. Medicine (Baltimore) 97:e10786. https:\/\/doi.org\/10.1097\/MD.0000000000010786","journal-title":"Medicine (Baltimore)"},{"key":"4521_CR6","first-page":"1485","volume":"26","author":"Z Wu","year":"2021","unstructured":"Wu Z, Fang H (2021) Efficacy of paclitaxel and S-1 combined with apatinib in the conversion therapy for unresectable advanced gastric cancer. J BUON 26:1485\u20131490","journal-title":"J BUON"},{"key":"4521_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-020-00774-4","volume":"21","author":"TH Patel","year":"2020","unstructured":"Patel TH, Cecchini M (2020) Targeted therapies in advanced gastric cancer. Curr Treat Options Oncol 21:70. https:\/\/doi.org\/10.1007\/s11864-020-00774-4","journal-title":"Curr Treat Options Oncol"},{"key":"4521_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00280-021-04322-1","volume":"88","author":"Y Liao","year":"2021","unstructured":"Liao Y, Chen W, Shi W, Zha H (2021) Targeting cPLA2\u03b1 inhibits gastric cancer and augments chemotherapy efficacy via suppressing Ras\/MEK\/ERK and Akt\/\u03b2-catenin pathways. Cancer Chemother Pharmacol 88:689\u2013697. https:\/\/doi.org\/10.1007\/s00280-021-04322-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"4521_CR9","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1080\/15548627.2021.1901204","volume":"17","author":"Y Luo","year":"2021","unstructured":"Luo Y, Zheng S, Wu Q et al (2021) Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation. Autophagy 17:4083\u20134101. https:\/\/doi.org\/10.1080\/15548627.2021.1901204","journal-title":"Autophagy"},{"key":"4521_CR10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1007\/s10120-020-01088-y","volume":"23","author":"R Peng","year":"2020","unstructured":"Peng R, Chen Y, Wei L et al (2020) Resistance to FGFR1-targeted therapy leads to autophagy via TAK1\/AMPK activation in gastric cancer. Gastric Cancer 23:988\u20131002. https:\/\/doi.org\/10.1007\/s10120-020-01088-y","journal-title":"Gastric Cancer"},{"key":"4521_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1358\/dot.2020.56.7.3112071","volume":"56","author":"Z Chen","year":"2020","unstructured":"Chen Z, Li Y, Tan B et al (2020) Progress and current status of molecule-targeted therapy and drug resistance in gastric cancer. Drugs Today (Barc) 56:469\u2013482. https:\/\/doi.org\/10.1358\/dot.2020.56.7.3112071","journal-title":"Drugs Today (Barc)"},{"key":"4521_CR12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2174\/1389450120666191127113854","volume":"21","author":"LV Spirina","year":"2020","unstructured":"Spirina LV, Avgustinovich AV, Afanas\u2019ev SG et al (2020) Molecular mechanism of resistance to chemotherapy in gastric cancers, the role of autophagy. Curr Drug Targets 21:713\u2013721. https:\/\/doi.org\/10.2174\/1389450120666191127113854","journal-title":"Curr Drug Targets"},{"key":"4521_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1021\/np50033a001","volume":"47","author":"W Wiegrebe","year":"1984","unstructured":"Wiegrebe W, Kramer WJ, Shamma M (1984) The emetine alkaloids. J Nat Prod 47:397\u2013408. https:\/\/doi.org\/10.1021\/np50033a001","journal-title":"J Nat Prod"},{"key":"4521_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1136\/bmj.1.2978.116","volume":"1","author":"AC Lambert","year":"1918","unstructured":"Lambert AC (1918) The treatment of amoebic dysentery with emetine and bismuth iodide. Br Med J 1:116\u2013118. https:\/\/doi.org\/10.1136\/bmj.1.2978.116","journal-title":"Br Med J"},{"key":"4521_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41421-018-0034-1","volume":"4","author":"S Yang","year":"2018","unstructured":"Yang S, Xu M, Lee EM et al (2018) Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discov 4:31. https:\/\/doi.org\/10.1038\/s41421-018-0034-1","journal-title":"Cell Discov"},{"key":"4521_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s43556-020-00018-9","volume":"1","author":"A Wang","year":"2020","unstructured":"Wang A, Sun Y, Liu Q et al (2020) Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences. Mol Biomed 1:14. https:\/\/doi.org\/10.1186\/s43556-020-00018-9","journal-title":"Mol Biomed"},{"key":"4521_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jama.1918.02600010007002","volume":"70","author":"R Lewisohn","year":"1918","unstructured":"Lewisohn R (1918) Action of emetine on malignant tumors. J Am Med Assoc 70:9\u201310. https:\/\/doi.org\/10.1001\/jama.1918.02600010007002","journal-title":"J Am Med Assoc"},{"key":"4521_CR18","first-page":"1171","volume":"59","author":"RC Kane","year":"1975","unstructured":"Kane RC, Cohen MH, Broder LE et al (1975) Phase I-II evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma. Cancer Chemother Rep 59:1171\u20131172","journal-title":"Cancer Chemother Rep"},{"key":"4521_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1006\/taap.1998.8616","volume":"156","author":"I Meijerman","year":"1999","unstructured":"Meijerman I, Blom WM, de Bont HJ et al (1999) Induction of apoptosis and changes in nuclear G-actin are mediated by different pathways: the effect of inhibitors of protein and RNA synthesis in isolated rat hepatocytes. Toxicol Appl Pharmacol 156:46\u201355. https:\/\/doi.org\/10.1006\/taap.1998.8616","journal-title":"Toxicol Appl Pharmacol"},{"key":"4521_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1021\/np050029m","volume":"68","author":"Y-D Zhou","year":"2005","unstructured":"Zhou Y-D, Kim Y-P, Mohammed KA et al (2005) Terpenoid tetrahydroisoquinoline alkaloids emetine, klugine, and isocephaeline inhibit the activation of hypoxia-inducible factor-1 in breast tumor cells. J Nat Prod 68:947\u2013950. https:\/\/doi.org\/10.1021\/np050029m","journal-title":"J Nat Prod"},{"key":"4521_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/1874848101104010008","volume":"411","author":"ES Akinboye","year":"2011","unstructured":"Akinboye ES, Bakare O (2011) Biological activities of emetine. Open Nat Prod J 411:8\u201315. https:\/\/doi.org\/10.2174\/1874848101104010008","journal-title":"Open Nat Prod J"},{"key":"4521_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41375-019-0513-x","volume":"34","author":"DY Yosifov","year":"2020","unstructured":"Yosifov DY, Idler I, Bhattacharya N et al (2020) Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. Leukemia 34:115\u2013127. https:\/\/doi.org\/10.1038\/s41375-019-0513-x","journal-title":"Leukemia"},{"key":"4521_CR23","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7290","author":"Q Sun","year":"2019","unstructured":"Sun Q, Fu Q, Li S et al (2019) Emetine exhibits anticancer activity in breast cancer cells as an antagonist of Wnt\/\u03b2-catenin signaling. Oncol Rep. https:\/\/doi.org\/10.3892\/or.2019.7290","journal-title":"Oncol Rep"},{"key":"4521_CR24","doi-asserted-by":"publisher","first-page":"E5914","DOI":"10.3390\/ijms20235914","volume":"20","author":"T-H Wu","year":"2019","unstructured":"Wu T-H, Chang S-Y, Shih Y-L et al (2019) Emetine synergizes with cisplatin to enhance anti-cancer efficacy against lung cancer cells. Int J Mol Sci 20:E5914. https:\/\/doi.org\/10.3390\/ijms20235914","journal-title":"Int J Mol Sci"},{"key":"4521_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cbi.2015.08.014","volume":"242","author":"JH Kim","year":"2015","unstructured":"Kim JH, Cho EB, Lee J et al (2015) Emetine inhibits migration and invasion of human non-small-cell lung cancer cells via regulation of ERK and p38 signaling pathways. Chem Biol Interact 242:25\u201333. https:\/\/doi.org\/10.1016\/j.cbi.2015.08.014","journal-title":"Chem Biol Interact"},{"key":"4521_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s13402-017-0322-z","volume":"40","author":"C Busonero","year":"2017","unstructured":"Busonero C, Leone S, Acconcia F (2017) Emetine induces estrogen receptor alpha degradation and prevents 17\u03b2-estradiol-induced breast cancer cell proliferation. Cell Oncol (Dordr) 40:299\u2013301. https:\/\/doi.org\/10.1007\/s13402-017-0322-z","journal-title":"Cell Oncol (Dordr)"},{"key":"4521_CR27","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1126\/science.270.5240.1326","volume":"270","author":"Z Xia","year":"1995","unstructured":"Xia Z, Dickens M, Raingeaud J et al (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326\u20131331. https:\/\/doi.org\/10.1126\/science.270.5240.1326","journal-title":"Science"},{"key":"4521_CR28","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.2147\/OTT.S240803","volume":"13","author":"Q Zhu","year":"2020","unstructured":"Zhu Q, Guo Y, Chen S et al (2020) Irinotecan induces autophagy-dependent apoptosis and positively regulates ROS-related JNK- and P38-MAPK pathways in gastric cancer cells. Onco Targets Ther 13:2807\u20132817. https:\/\/doi.org\/10.2147\/OTT.S240803","journal-title":"Onco Targets Ther"},{"key":"4521_CR29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330\u2013338. https:\/\/doi.org\/10.1038\/nrc1074","journal-title":"Nat Rev Cancer"},{"key":"4521_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.17179\/excli2016-280","volume":"15","author":"PF Uzor","year":"2016","unstructured":"Uzor PF (2016) Recent developments on potential new applications of emetine as anti-cancer agent. EXCLI J 15:323\u2013328. https:\/\/doi.org\/10.17179\/excli2016-280","journal-title":"EXCLI J"},{"key":"4521_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22868","author":"J Son","year":"2021","unstructured":"Son J, Lee SY (2021) Emetine exerts anticancer effects in U2OS human osteosarcoma cells via activation of p38 and inhibition of ERK, JNK, and \u03b2-catenin signaling pathways. J Biochem Mol Toxicol. https:\/\/doi.org\/10.1002\/jbt.22868","journal-title":"J Biochem Mol Toxicol"},{"key":"4521_CR32","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7295","author":"S Kim","year":"2019","unstructured":"Kim S, Choo G, Yoo E et al (2019) Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells. Oncol Rep. https:\/\/doi.org\/10.3892\/or.2019.7295","journal-title":"Oncol Rep"},{"key":"4521_CR33","first-page":"1852","volume":"34","author":"K Li","year":"2014","unstructured":"Li K, Dan Z (2014) Research progress of Wnt\/\u03b2-catenin signaling pathway in prevention and treatment of gastric cancer. Nan Fang Yi Ke Da Xue Xue Bao 34:1852\u20131856","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"4521_CR34","doi-asserted-by":"publisher","first-page":"E3927","DOI":"10.3390\/ijms21113927","volume":"21","author":"S Koushyar","year":"2020","unstructured":"Koushyar S, Powell AG, Vincan E, Phesse TJ (2020) Targeting Wnt signaling for the treatment of gastric cancer. Int J Mol Sci 21:E3927. https:\/\/doi.org\/10.3390\/ijms21113927","journal-title":"Int J Mol Sci"},{"key":"4521_CR35","doi-asserted-by":"publisher","first-page":"e000728","DOI":"10.1136\/esmoopen-2020-000728","volume":"5","author":"BW Kang","year":"2020","unstructured":"Kang BW, Chau I (2020) Molecular target: pan-AKT in gastric cancer. ESMO Open 5:e000728. https:\/\/doi.org\/10.1136\/esmoopen-2020-000728","journal-title":"ESMO Open"},{"key":"4521_CR36","doi-asserted-by":"publisher","first-page":"173983","DOI":"10.1016\/j.ejphar.2021.173983","volume":"898","author":"A Baghery Saghchy Khorasani","year":"2021","unstructured":"Baghery Saghchy Khorasani A, Pourbagheri-Sigaroodi A, Pirsalehi A et al (2021) The PI3K\/Akt\/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions. Eur J Pharmacol 898:173983. https:\/\/doi.org\/10.1016\/j.ejphar.2021.173983","journal-title":"Eur J Pharmacol"},{"key":"4521_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.11.017","volume":"108","author":"Y-J Bang","year":"2019","unstructured":"Bang Y-J, Kang Y-K, Ng M et al (2019) A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Eur J Cancer 108:17\u201324. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.017","journal-title":"Eur J Cancer"},{"key":"4521_CR38","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/2159-8290.CD-19-0442","volume":"9","author":"J Lee","year":"2019","unstructured":"Lee J, Kim ST, Kim K et al (2019) Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discov 9:1388\u20131405. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0442","journal-title":"Cancer Discov"},{"key":"4521_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ccr.2014.01.010","volume":"25","author":"S Jiao","year":"2014","unstructured":"Jiao S, Wang H, Shi Z et al (2014) A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 25:166\u2013180. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.010","journal-title":"Cancer Cell"},{"key":"4521_CR40","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-10-2467","volume":"17","author":"W Kang","year":"2011","unstructured":"Kang W, Tong JHM, Chan AWH et al (2011) Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res 17:2130\u20132139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2467","journal-title":"Clin Cancer Res"},{"key":"4521_CR41","doi-asserted-by":"publisher","first-page":"E2011","DOI":"10.3390\/cancers12082011","volume":"12","author":"L Seeneevassen","year":"2020","unstructured":"Seeneevassen L, Giraud J, Molina-Castro S et al (2020) Leukaemia inhibitory factor (LIF) inhibits cancer stem cells tumorigenic properties through hippo kinases activation in gastric cancer. Cancers (Basel) 12:E2011. https:\/\/doi.org\/10.3390\/cancers12082011","journal-title":"Cancers (Basel)"},{"key":"4521_CR42","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1038\/s41388-018-0204-5","volume":"37","author":"J Shi","year":"2018","unstructured":"Shi J, Li F, Yao X et al (2018) The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. Oncogene 37:3022\u20133038. https:\/\/doi.org\/10.1038\/s41388-018-0204-5","journal-title":"Oncogene"},{"key":"4521_CR43","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.3390\/cancers14092282","volume":"14","author":"L Seeneevassen","year":"2022","unstructured":"Seeneevassen L, Dubus P, Gronnier C, Varon C (2022) Hippo in gastric cancer: from signalling to therapy. Cancers (Basel) 14:2282. https:\/\/doi.org\/10.3390\/cancers14092282","journal-title":"Cancers (Basel)"},{"key":"4521_CR44","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/1097-0142(197104)27:4<835::aid-cncr2820270413>3.0.co;2-k","volume":"27","author":"F Panettiere","year":"1971","unstructured":"Panettiere F, Coltman CA (1971) Experience with emetine hydrochloride (NSC 33669) as an antitumor agent. Cancer 27:835\u2013841. https:\/\/doi.org\/10.1002\/1097-0142(197104)27:4%3c835::aid-cncr2820270413%3e3.0.co;2-k","journal-title":"Cancer"},{"key":"4521_CR45","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/1097-0142(197305)31:5<1170::aid-cncr2820310520>3.0.co;2-4","volume":"31","author":"MJ Mastrangelo","year":"1973","unstructured":"Mastrangelo MJ, Grage TB, Bellet RE, Weiss AJ (1973) A phase I study of emetine hydrochloride (NSC 33669) in solid tumors. Cancer 31:1170\u20131175. https:\/\/doi.org\/10.1002\/1097-0142(197305)31:5%3c1170::aid-cncr2820310520%3e3.0.co;2-4","journal-title":"Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04521-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04521-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04521-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:44:28Z","timestamp":1744159468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04521-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["4521"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04521-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,20]]},"assertion":[{"value":"22 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving animals were in accordance with the ethical standards of the Animal Care and Use Committee of Sichuan Academy of Medical Sciences and Sichuan Provincial People\u2019s Hospital (Chengdu, Sichuan, China).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Formal consent is not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}